| The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe ZM Younossi, D Blissett, R Blissett, L Henry, M Stepanova, Y Younossi, ... Hepatology 64 (5), 1577-1586, 2016 | 1395 | 2016 |
| Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States ZM Younossi, M Stepanova, J Ong, G Trimble, S AlQahtani, I Younossi, ... Clinical Gastroenterology and Hepatology 19 (3), 580-589. e5, 2021 | 452 | 2021 |
| Mortality related to nonalcoholic fatty liver disease is increasing in the United States JM Paik, L Henry, L De Avila, E Younossi, A Racila, ZM Younossi Hepatology Communications 3 (11), 1459-1471, 2019 | 217 | 2019 |
| Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States ZM Younossi, R Tampi, M Priyadarshini, F Nader, IM Younossi, A Racila Hepatology 69 (2), 564-572, 2019 | 212 | 2019 |
| Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the US ZM Younossi, RP Tampi, A Racila, Y Qiu, L Burns, I Younossi, F Nader Diabetes care 43 (2), 283-289, 2020 | 163 | 2020 |
| A disease‐specific quality of life instrument for non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis: CLDQ‐NAFLD ZM Younossi, M Stepanova, L Henry, A Racila, B Lam, HT Pham, S Hunt Liver International 37 (8), 1209-1218, 2017 | 107 | 2017 |
| A global survey of physicians knowledge about nonalcoholic fatty liver disease ZM Younossi, JP Ong, H Takahashi, Y Yilmaz, Y Eguchi, M El Kassas, ... Clinical Gastroenterology and Hepatology 20 (6), e1456-e1468, 2022 | 85 | 2022 |
| Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate coronavirus disease 2019 (COVID-19): a real-world experience JP Verderese, M Stepanova, B Lam, A Racila, A Kolacevski, D Allen, ... Clinical Infectious Diseases 74 (6), 1063-1069, 2022 | 85 | 2022 |
| Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the global non-alcoholic steatohepatitis (NASH)/non … ZM Younossi, Y Yilmaz, ML Yu, VWS Wong, MC Fernandez, VA Isakov, ... Clinical Gastroenterology and Hepatology 20 (10), 2296-2306. e6, 2022 | 77 | 2022 |
| Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease ZM Younossi, SA Alqahtani, K Alswat, Y Yilmaz, C Keklikkiran, ... Journal of hepatology 80 (3), 419-430, 2024 | 62 | 2024 |
| Patients with nonalcoholic steatohepatitis experience severe impairment of health-related quality of life ZM Younossi, M Stepanova, EJ Lawitz, KR Reddy, VWS Wong, A Mangia, ... Official journal of the American College of Gastroenterology| ACG 114 (10 …, 2019 | 59 | 2019 |
| Independent predictors of mortality among patients with NAFLD hospitalized with COVID‐19 infection ZM Younossi, M Stepanova, B Lam, R Cable, S Felix, T Jeffers, ... Hepatology communications 6 (11), 3062-3072, 2022 | 51 | 2022 |
| Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease ZM Younossi, S Felix, T Jeffers, E Younossi, F Nader, H Pham, A Afendy, ... JAMA network open 4 (9), e2123923-e2123923, 2021 | 51 | 2021 |
| Validation of chronic liver disease questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis ZM Younossi, M Stepanova, I Younossi, A Racila Clinical Gastroenterology and Hepatology 17 (10), 2093-2100. e3, 2019 | 51 | 2019 |
| Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naive chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3 ZM Younossi, M Stepanova, IM Jacobson, T Asselah, EJ Gane, E Lawitz, ... Alimentary pharmacology & therapeutics 47 (2), 259-267, 2018 | 51 | 2018 |
| Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: the PSC PRO ZM Younossi, A Afendy, M Stepanova, A Racila, F Nader, R Gomel, ... Hepatology 68 (1), 155-165, 2018 | 41 | 2018 |
| Effects of treatment of chronic hepatitis B virus infection on patient-reported outcomes ZM Younossi, M Stepanova, HLA Janssen, K Agarwal, MH Nguyen, ... Clinical Gastroenterology and Hepatology 16 (10), 1641-1649. e6, 2018 | 36 | 2018 |
| Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor M Stepanova, M Sayiner, L de Avila, Z Younoszai, A Racila, ZM Younossi BMC gastroenterology 16, 1-6, 2016 | 34 | 2016 |
| Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis M Harring, P Golabi, JM Paik, D Shah, A Racila, R Cable, M Srishord, ... Clinical Gastroenterology and Hepatology 21 (11), 2876-2888. e5, 2023 | 33 | 2023 |
| Primary biliary cholangitis in Medicare population: the impact on mortality and resource use M Sayiner, P Golabi, M Stepanova, I Younossi, F Nader, A Racila, ... Hepatology 69 (1), 237-244, 2019 | 29 | 2019 |